SMT202000430T1 - Forme cristalline di 2-(terz-butilammino)-4-((1r,3r,4r)-3-idrossi-4-metilcilcloesilammino)-pirimidin-5-carbossammide - Google Patents

Forme cristalline di 2-(terz-butilammino)-4-((1r,3r,4r)-3-idrossi-4-metilcilcloesilammino)-pirimidin-5-carbossammide

Info

Publication number: SMT202000430T1
Authority: SM; San Marino
Prior art keywords: methylcyclohexylamino; butylamino; carboxamide; pyrimidine; tert
Prior art date: 2014-01-30

Application number

SM20200430T

Other languages

English (en)

Inventor

Hon-Wah Man

Ying Li

Jean Xu

Antonio Christian Ferretti

Jale Muslehiddinoglu

Kelvin Hin-Yeong Yong

Marie Georges Beauchamps

Mohit Atul Kothare

Nanfei Zou

Nathan Andrew Boersen

Robert Hilgraf

Mark A Nagy

Daozhong Zou

Lianfeng Huang

Original Assignee

Signal Pharm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-30

Filing date

2015-01-29

Publication date

2020-09-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53678405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202000430(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-01-29 Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc

2020-09-10 Publication of SMT202000430T1 publication Critical patent/SMT202000430T1/it

Links

QBBRJRLJWXRSHQ-CKYFFXLPSA-N 2-(tert-butylamino)-4-[[(1r,3r,4r)-3-hydroxy-4-methylcyclohexyl]amino]pyrimidine-5-carboxamide Chemical compound C1[C@@H](O)[C@H](C)CC[C@H]1NC1=NC(NC(C)(C)C)=NC=C1C(N)=O QBBRJRLJWXRSHQ-CKYFFXLPSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Obesity (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Cosmetics (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SM20200430T 2014-01-30 2015-01-29 Forme cristalline di 2-(terz-butilammino)-4-((1r,3r,4r)-3-idrossi-4-metilcilcloesilammino)-pirimidin-5-carbossammide SMT202000430T1 (it)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201461933636P	2014-01-30	2014-01-30
US201462025161P	2014-07-16	2014-07-16
EP15743503.3A EP3099302B1 (en)	2014-01-30	2015-01-29	Crystalline forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
PCT/US2015/013412 WO2015116755A2 (en)	2014-01-30	2015-01-29	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use

Publications (1)

Publication Number	Publication Date
SMT202000430T1 true SMT202000430T1 (it)	2020-09-10

Family

ID=53678405

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20200430T SMT202000430T1 (it)	2014-01-30	2015-01-29	Forme cristalline di 2-(terz-butilammino)-4-((1r,3r,4r)-3-idrossi-4-metilcilcloesilammino)-pirimidin-5-carbossammide

Country Status (32)

Country	Link
US (7)	US9365524B2 (it)
EP (2)	EP3738954A1 (it)
JP (3)	JP2017504632A (it)
KR (2)	KR102760889B1 (it)
CN (3)	CN113717110A (it)
AU (2)	AU2015211036B2 (it)
BR (2)	BR112016017776A8 (it)
CA (1)	CA2938187C (it)
CL (1)	CL2016001927A1 (it)
CR (1)	CR20160346A (it)
CY (1)	CY1123267T1 (it)
DK (1)	DK3099302T3 (it)
EA (2)	EA031671B1 (it)
ES (1)	ES2811834T3 (it)
HR (1)	HRP20201244T1 (it)
HU (1)	HUE051266T2 (it)
IL (2)	IL246931B (it)
LT (1)	LT3099302T (it)
MX (3)	MX391127B (it)
MY (1)	MY180020A (it)
NZ (3)	NZ715903A (it)
PE (1)	PE20161437A1 (it)
PH (1)	PH12016501472B1 (it)
PL (1)	PL3099302T3 (it)
PT (1)	PT3099302T (it)
RS (1)	RS60715B1 (it)
SA (1)	SA516371578B1 (it)
SG (1)	SG11201606054SA (it)
SI (1)	SI3099302T1 (it)
SM (1)	SMT202000430T1 (it)
TW (1)	TWI631108B (it)
WO (1)	WO2015116755A2 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20240097T1 (hr)	2011-04-22	2024-03-29	Signal Pharmaceuticals, Llc	Supstituirani diaminokarboksamid i diaminokarbonitril pirimidini, njihovi pripravci i postupci liječenja s njima
NZ715903A (en)	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2016100310A1 (en)	2014-12-16	2016-06-23	Signal Pharmaceuticals, Llc	Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
EP3233808B1 (en)	2014-12-16	2021-07-14	Signal Pharmaceuticals, LLC	Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
CA2975260C (en)	2015-01-29	2024-05-21	Signal Pharmaceuticals Llc	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
ES2994877T3 (en)	2015-07-24	2025-02-03	Celgene Corp	Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
CN111934089B (zh)	2019-05-13	2021-10-26	华为技术有限公司	天线装置及移动终端
CN113698408B (zh) *	2020-05-22	2025-07-25	武汉朗来科技发展有限公司	Jnk抑制剂、其药物组合物和用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH549339A (de)	1971-05-12	1974-05-31	Ciba Geigy Ag	Herbizides mittel.
US5852028A (en) *	1995-12-18	1998-12-22	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5811428A (en) *	1995-12-18	1998-09-22	Signal Pharmaceuticals, Inc.	Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5935966A (en) *	1995-09-01	1999-08-10	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
AU1507199A (en)	1997-12-15	1999-07-05	Yamanouchi Pharmaceutical Co., Ltd.	Novel pyrimidine-5-carboxamide derivatives
DE69933680T2 (de)	1998-08-29	2007-08-23	Astrazeneca Ab	Pyrimidine verbindungen
AU5107900A (en)	1999-06-09	2000-12-28	Yamanouchi Pharmaceutical Co., Ltd.	Novel heterocyclic carboxamide derivatives
AU5108000A (en)	1999-06-10	2001-01-02	Yamanouchi Pharmaceutical Co., Ltd.	Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
US7122544B2 (en) *	2000-12-06	2006-10-17	Signal Pharmaceuticals, Llc	Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) *	2000-12-06	2006-10-31	Signal Pharmaceuticals, Llc	Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7429599B2 (en) *	2000-12-06	2008-09-30	Signal Pharmaceuticals, Llc	Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
AU2003220968A1 (en)	2002-03-28	2003-10-13	Kyowa Hakko Kogyo Co., Ltd.	Anti-inflammatory agent
EP1518855B1 (en) *	2002-06-28	2011-10-26	Astellas Pharma Inc.	Diaminopyrimidinecarboxa mide derivative
BR0313059B8 (pt)	2002-07-29	2021-07-27	Rigel Pharmaceuticals	composto, e, composição farmacêutica
WO2004053071A2 (en) *	2002-12-09	2004-06-24	Judith Kelleher-Andersson	Method for discovering neurogenic agents
WO2004054617A1 (ja)	2002-12-13	2004-07-01	Kyowa Hakko Kogyo Co., Ltd.	中枢疾患の予防および／または治療剤
DE602004022633D1 (de)	2003-01-30	2009-10-01	Boehringer Ingelheim Pharma	2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
TWI378923B (en)	2003-08-15	2012-12-11	Novartis Ag	Pyrimidine derivatives
CN1871009A (zh)	2003-09-24	2006-11-29	惠氏控股公司	作为抗癌剂的5－芳基嘧啶
WO2005095382A1 (ja)	2004-03-30	2005-10-13	Kyowa Hakko Kogyo Co., Ltd.	抗腫瘍剤
WO2006014482A1 (en)	2004-07-08	2006-02-09	Boehringer Ingelheim Pharmaceuticals, Inc.	Pyrimidine derivatives useful as inhibitors of pkc-theta
JP2008512429A (ja)	2004-09-10	2008-04-24	ニコメッドゲゼルシャフトミットベシュレンクテルハフツング	ロフルミラストとｓｙｋインヒビターとの組合せ物並びにその使用方法
EP1796679A1 (en)	2004-09-10	2007-06-20	Altana Pharma AG	Ciclesonide and syk inhibitor combination and methods of use thereof
JP2006124387A (ja)	2004-09-30	2006-05-18	Taisho Pharmaceut Co Ltd	新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
RU2410379C2 (ru)	2004-09-30	2011-01-27	Тиботек Фармасьютикалз Лтд.	5-замещенные пиримидины, ингибирующие вич
WO2006091737A1 (en)	2005-02-24	2006-08-31	Kemia, Inc.	Modulators of gsk-3 activity
WO2006099231A1 (en)	2005-03-10	2006-09-21	Bayer Pharmaceuticals Corporation	Pyrimidine derivatives for treatment of hyperproliferative disorders
DE102005062742A1 (de) *	2005-12-22	2007-06-28	Bayer Schering Pharma Ag	Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
CA2657260A1 (en)	2006-07-21	2008-01-24	Novartis Ag	2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
US20080139531A1 (en)	2006-12-04	2008-06-12	Alcon Manufacturing Ltd.	Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
AP2009005010A0 (en)	2007-04-18	2009-10-31	Pfizer Prod Inc	Sulfonyl amide derivatives for the treatment of abnormal cell growth
US20090036440A1 (en)	2007-04-27	2009-02-05	Astrazeneca Ab	Novel pyrimidine derivatives - 816
WO2009010789A2 (en)	2007-07-16	2009-01-22	Astrazeneca Ab	Pyrimidine derivatives 934
CN101903357A (zh)	2007-07-17	2010-12-01	里格尔药品股份有限公司	作为pkc抑制剂的环状胺取代的嘧啶二胺
JP5705720B2 (ja) *	2008-04-16	2015-04-22	ポートラファーマシューティカルズ，インコーポレイテッド	Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド
KR20100132550A (ko)	2008-04-16	2010-12-17	포톨라 파마슈티컬스, 인코포레이티드	ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
JP2011518219A (ja)	2008-04-22	2011-06-23	ポートラファーマシューティカルズ，インコーポレイテッド	タンパク質キナーゼの阻害剤
EP2300013B2 (en)	2008-05-21	2024-11-13	Takeda Pharmaceutical Company Limited	Phosphorous derivatives as kinase inhibitors
UY31929A (es)	2008-06-25	2010-01-05	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
NZ603525A (en)	2008-06-27	2015-02-27	Celgene Avilomics Res Inc	Pyrimidine based compound and uses thereof
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010024430A1 (ja)	2008-09-01	2010-03-04	アステラス製薬株式会社	2,4-ジアミノピリミジン化合物
CA2737738A1 (en)	2008-09-18	2010-03-25	Astellas Pharma Inc.	Heterocyclic carboxamide compounds
TW201016676A (en)	2008-10-03	2010-05-01	Astrazeneca Ab	Heterocyclic derivatives and methods of use thereof
CN102272291B (zh)	2008-10-31	2018-01-16	詹森生物科技公司	人胚胎干细胞向胰腺内分泌谱系的分化
EP2375899B1 (en)	2009-01-12	2015-02-25	Array Biopharma Inc.	Piperidine-containing compounds and use thereof in the treatment of diabetes
MX2011007499A (es) *	2009-01-13	2011-08-04	Glaxo Group Ltd	Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
ES2635504T3 (es)	2009-01-21	2017-10-04	Rigel Pharmaceuticals, Inc.	Derivados de N2-(3-piridilo o fenil)-N4-(4-piperidil)-2,4-pirimidinadiamina útiles en el tratamiento de enfermedades inflamatorias, toimmunitarias o proliferativas
US8367689B2 (en) *	2009-05-06	2013-02-05	Portola Pharmaceuticals, Inc.	Inhibitors of JAK
JP5364159B2 (ja) *	2009-05-08	2013-12-11	アステラス製薬株式会社	ジアミノへテロ環カルボキサミド化合物
CN102498110A (zh)	2009-06-10	2012-06-13	雅培制药有限公司	作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶
JP2012197231A (ja)	2009-08-06	2012-10-18	Oncotherapy Science Ltd	Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
WO2011065800A2 (ko)	2009-11-30	2011-06-03	주식회사 오스코텍	피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
US20110130415A1 (en) *	2009-12-01	2011-06-02	Rajinder Singh	Protein kinase c inhibitors and uses thereof
JP6035238B2 (ja)	2010-07-21	2016-11-30	ライジェルファーマシューティカルズ，インコーポレイテッド	プロテインキナーゼｃ阻害剤およびその使用
US8580805B2 (en) *	2010-08-31	2013-11-12	Hubert Maehr	Pyrimidine carboxamide derivatives
WO2012044936A1 (en)	2010-09-30	2012-04-05	Portola Pharmaceuticals, Inc.	Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
WO2012045010A1 (en)	2010-09-30	2012-04-05	Portola Pharmaceuticals, Inc.	Combinations of 4-(3-(2h-1,2,3-triazo-2-yl) phenylamino)-2-((1r,2s)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine
HRP20240097T1 (hr) *	2011-04-22	2024-03-29	Signal Pharmaceuticals, Llc	Supstituirani diaminokarboksamid i diaminokarbonitril pirimidini, njihovi pripravci i postupci liječenja s njima
WO2013152198A1 (en) *	2012-04-04	2013-10-10	Rigel Pharmaceuticals, Inc.	Protein kinase c inhibitors and uses thereof
CA2892677A1 (en) *	2012-12-04	2014-06-12	Rigel Pharmaceuticals, Inc.	Protein kinase c inhibitors and uses thereof
CA2904610A1 (en) *	2013-03-14	2014-09-25	Rigel Pharmaceuticals, Inc.	Protein kinase c inhibitors and uses thereof
CN104262328B (zh) *	2013-09-18	2016-09-07	北京韩美药品有限公司	抑制btk和/或jak3激酶活性的化合物
AR099376A1 (es) *	2013-12-20	2016-07-20	Signal Pharm Llc	Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos
NZ715903A (en) *	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2016100310A1 (en) *	2014-12-16	2016-06-23	Signal Pharmaceuticals, Llc	Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
CA2975260C (en) *	2015-01-29	2024-05-21	Signal Pharmaceuticals Llc	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide

2014
- 2014-09-03 NZ NZ715903A patent/NZ715903A/en unknown
2015
- 2015-01-29 EA EA201691544A patent/EA031671B1/ru not_active IP Right Cessation
- 2015-01-29 MX MX2020003173A patent/MX391127B/es unknown
- 2015-01-29 MY MYPI2016702761A patent/MY180020A/en unknown
- 2015-01-29 US US14/608,314 patent/US9365524B2/en active Active
- 2015-01-29 NZ NZ722412A patent/NZ722412A/en unknown
- 2015-01-29 SM SM20200430T patent/SMT202000430T1/it unknown
- 2015-01-29 HU HUE15743503A patent/HUE051266T2/hu unknown
- 2015-01-29 TW TW104103137A patent/TWI631108B/zh active
- 2015-01-29 NZ NZ761068A patent/NZ761068A/en unknown
- 2015-01-29 SG SG11201606054SA patent/SG11201606054SA/en unknown
- 2015-01-29 CA CA2938187A patent/CA2938187C/en active Active
- 2015-01-29 CN CN202110386098.9A patent/CN113717110A/zh active Pending
- 2015-01-29 HR HRP20201244TT patent/HRP20201244T1/hr unknown
- 2015-01-29 DK DK15743503.3T patent/DK3099302T3/da active
- 2015-01-29 PT PT157435033T patent/PT3099302T/pt unknown
- 2015-01-29 AU AU2015211036A patent/AU2015211036B2/en active Active
- 2015-01-29 CR CR20160346A patent/CR20160346A/es unknown
- 2015-01-29 MX MX2016009989A patent/MX373804B/es active IP Right Grant
- 2015-01-29 EP EP20178344.6A patent/EP3738954A1/en active Pending
- 2015-01-29 KR KR1020227013115A patent/KR102760889B1/ko active Active
- 2015-01-29 SI SI201531322T patent/SI3099302T1/sl unknown
- 2015-01-29 JP JP2016549045A patent/JP2017504632A/ja active Pending
- 2015-01-29 CN CN202110386057.XA patent/CN113717109A/zh active Pending
- 2015-01-29 BR BR112016017776A patent/BR112016017776A8/pt not_active Application Discontinuation
- 2015-01-29 CN CN201580016658.4A patent/CN106163523A/zh active Pending
- 2015-01-29 RS RS20200970A patent/RS60715B1/sr unknown
- 2015-01-29 ES ES15743503T patent/ES2811834T3/es active Active
- 2015-01-29 BR BR122020003206-5A patent/BR122020003206B1/pt active IP Right Grant
- 2015-01-29 KR KR1020167023497A patent/KR102505677B1/ko active Active
- 2015-01-29 EP EP15743503.3A patent/EP3099302B1/en active Active
- 2015-01-29 LT LTEP15743503.3T patent/LT3099302T/lt unknown
- 2015-01-29 PL PL15743503T patent/PL3099302T3/pl unknown
- 2015-01-29 PE PE2016001300A patent/PE20161437A1/es not_active Application Discontinuation
- 2015-01-29 WO PCT/US2015/013412 patent/WO2015116755A2/en not_active Ceased
- 2015-01-29 EA EA201792281A patent/EA036964B1/ru not_active IP Right Cessation
2016
- 2016-05-12 US US15/152,653 patent/US9814713B2/en active Active
- 2016-07-25 IL IL246931A patent/IL246931B/en active IP Right Grant
- 2016-07-26 PH PH12016501472A patent/PH12016501472B1/en unknown
- 2016-07-28 SA SA516371578A patent/SA516371578B1/ar unknown
- 2016-07-29 MX MX2019005715A patent/MX2019005715A/es unknown
- 2016-07-29 CL CL2016001927A patent/CL2016001927A1/es unknown
2017
- 2017-10-09 US US15/727,659 patent/US10226461B2/en active Active
2019
- 2019-02-04 US US16/266,793 patent/US10517873B2/en active Active
- 2019-04-03 JP JP2019071044A patent/JP6742466B2/ja active Active
- 2019-11-11 US US16/679,592 patent/US11241430B2/en active Active
2020
- 2020-03-26 AU AU2020202146A patent/AU2020202146B2/en active Active
- 2020-06-11 IL IL275305A patent/IL275305B/en unknown
- 2020-07-28 JP JP2020127493A patent/JP7317768B2/ja active Active
- 2020-08-12 CY CY20201100757T patent/CY1123267T1/el unknown
2021
- 2021-12-27 US US17/562,933 patent/US20220378785A1/en not_active Abandoned
2024
- 2024-06-26 US US18/754,494 patent/US20250000860A1/en active Pending

Also Published As

Publication number	Publication date
AU2020202146A1 (en)	2020-04-16
IL275305B (en)	2021-12-01
HUE051266T2 (hu)	2021-03-01
CY1123267T1 (el)	2021-12-31
WO2015116755A2 (en)	2015-08-06
BR122020003206B1 (pt)	2023-02-07
JP2019142893A (ja)	2019-08-29
AU2015211036B2 (en)	2020-05-21
SG11201606054SA (en)	2016-08-30
LT3099302T (lt)	2020-09-10
MX2019005715A (es)	2019-08-12
KR20220051440A (ko)	2022-04-26
EP3099302A2 (en)	2016-12-07
CN113717110A (zh)	2021-11-30
PH12016501472A1 (en)	2016-08-22
PH12016501472B1 (en)	2019-05-31
CR20160346A (es)	2016-11-23
ES2811834T3 (es)	2021-03-15
IL246931B (en)	2020-06-30
BR112016017776A2 (pt)	2017-08-08
US20190167678A1 (en)	2019-06-06
CN113717109A (zh)	2021-11-30
TWI631108B (zh)	2018-08-01
PT3099302T (pt)	2020-08-27
PL3099302T3 (pl)	2021-03-08
NZ761068A (en)	2023-02-24
DK3099302T3 (da)	2020-08-24
US20180028534A1 (en)	2018-02-01
EP3738954A1 (en)	2020-11-18
US11241430B2 (en)	2022-02-08
JP6742466B2 (ja)	2020-08-19
US20220378785A1 (en)	2022-12-01
JP2020183437A (ja)	2020-11-12
US20200078359A1 (en)	2020-03-12
US20150210650A1 (en)	2015-07-30
PE20161437A1 (es)	2017-01-07
NZ629885A (en)	2016-04-29
US9814713B2 (en)	2017-11-14
CL2016001927A1 (es)	2017-02-24
SA516371578B1 (ar)	2019-09-01
KR102505677B1 (ko)	2023-03-03
AU2020202146B2 (en)	2021-11-18
MX373804B (es)	2020-03-24
MX2016009989A (es)	2017-02-20
WO2015116755A3 (en)	2015-11-12
MX2020003173A (es)	2022-03-30
IL275305A (en)	2020-07-30
AU2015211036A1 (en)	2016-08-11
NZ722412A (en)	2022-10-28
EA036964B1 (ru)	2021-01-20
CA2938187A1 (en)	2015-08-06
US10517873B2 (en)	2019-12-31
US10226461B2 (en)	2019-03-12
US9365524B2 (en)	2016-06-14
EA201792281A1 (ru)	2018-03-30
TW201615627A (zh)	2016-05-01
CA2938187C (en)	2022-08-09
SI3099302T1 (sl)	2020-10-30
EP3099302B1 (en)	2020-06-17
RS60715B1 (sr)	2020-09-30
EA201691544A1 (ru)	2017-01-30
MY180020A (en)	2020-11-19
WO2015116755A8 (en)	2016-09-22
IL246931A0 (en)	2016-09-29
JP7317768B2 (ja)	2023-07-31
US20160256459A1 (en)	2016-09-08
EA031671B1 (ru)	2019-02-28
EP3099302A4 (en)	2017-10-04
KR20160113269A (ko)	2016-09-28
US20250000860A1 (en)	2025-01-02
NZ715903A (en)	2017-06-30
MX391127B (es)	2025-03-21
CN106163523A (zh)	2016-11-23
HRP20201244T1 (hr)	2020-11-13
BR112016017776A8 (pt)	2020-06-30
KR102760889B1 (ko)	2025-02-03
JP2017504632A (ja)	2017-02-09

Publication	Publication Date	Title
IL252900A0 (en)	2017-08-31	Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
IL257442A (en)	2018-04-30	Process for preparing parp inhibitor, crystalline forms and their uses
ZA201804137B (en)	2022-08-31	Compounds useful as kinase inhibitors
EP3250557A4 (en)	2018-06-20	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3136857A4 (en)	2017-09-20	Crystalline form of baricitinib
SI3099302T1 (sl)	2020-10-30	Kristalne oblike 2-(tert-butilamino)-4-((1r,3r,4r)-3-hidroksi-4-metilcikloheksilamino)- primidin-5-karboksamida
SI3380554T2 (sl)	2024-01-31	Kristalne oblike per-kloro-gama-ciklodekstrinov
PL3113773T3 (pl)	2020-05-18	Krystaliczne postaci grapiprantu
SG10202101979TA (en)	2021-04-29	Crystalline forms of c21h22ci2n4o2
HUE066360T2 (hu)	2024-07-28	Eravaciklin kristályformái
PL3110249T3 (pl)	2018-09-28	Sposób wytwarzania mikrokapsułek biobójczych
IL253479A0 (en)	2017-09-28	Crystalline forms of efinconazole
AU358832S (en)	2014-11-19	Ear tie for correction of prominent ear deformity
IL248918A0 (en)	2017-01-31	Crystal structure of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
PT3395819T (pt)	2023-07-05	Forma cristalina de derivado de aminopirano substituído
EP3212611A4 (en)	2018-05-30	Crystal forms of verapamil hydrochloride
GB201518589D0 (en)	2015-12-02	Crystalline form of tetraacetylethylenediamine
ZA201704927B (en)	2018-12-19	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide,compositions thereof and methods of their use
GB201402377D0 (en)	2014-03-26	Stable polymorph form B of tapentadol hydrochloride
CA3308777A1 (en)	2026-05-13	Crystalline forms of c21h22ci2n4o2